These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33833756)

  • 1. Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis.
    Luque-Tévar M; Perez-Sanchez C; Patiño-Trives AM; Barbarroja N; Arias de la Rosa I; Abalos-Aguilera MC; Marin-Sanz JA; Ruiz-Vilchez D; Ortega-Castro R; Font P; Lopez-Medina C; Romero-Gomez M; Rodriguez-Escalera C; Perez-Venegas J; Ruiz-Montesinos MD; Dominguez C; Romero-Barco C; Fernandez-Nebro A; Mena-Vazquez N; Marenco JL; Uceda-Montañez J; Toledo-Coello MD; Aguirre MA; Escudero-Contreras A; Collantes-Estevez E; Lopez-Pedrera C
    Front Immunol; 2021; 12():631662. PubMed ID: 33833756
    [No Abstract]   [Full Text] [Related]  

  • 2. Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis.
    Nguyen MVC; Baillet A; Romand X; Trocmé C; Courtier A; Marotte H; Thomas T; Soubrier M; Miossec P; Tébib J; Grange L; Toussaint B; Lequerré T; Vittecoq O; Gaudin P
    Joint Bone Spine; 2019 Mar; 86(2):195-201. PubMed ID: 29885551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis.
    Rodríguez-Martín E; Nieto-Gañán I; Hernández-Breijo B; Sobrino C; García-Hoz C; Bachiller J; Martínez-Feito A; Navarro-Compán V; Lapuente-Suanzes P; Bonilla G; Pascual-Salcedo D; Roy G; Jurado T; Nozal P; Vázquez-Díaz M; Balsa A; Villar LM; Plasencia-Rodríguez C
    Front Immunol; 2020; 11():1913. PubMed ID: 32973793
    [No Abstract]   [Full Text] [Related]  

  • 4. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
    Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP;
    Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients.
    Pérez-Sánchez C; Ruiz-Limón P; Aguirre MA; Jiménez-Gómez Y; Arias-de la Rosa I; Ábalos-Aguilera MC; Rodriguez-Ariza A; Castro-Villegas MC; Ortega-Castro R; Segui P; Martinez C; Gonzalez-Conejero R; Rodríguez-López S; Gonzalez-Reyes JA; Villalba JM; Collantes-Estévez E; Escudero A; Barbarroja N; López-Pedrera C
    J Autoimmun; 2017 Aug; 82():31-40. PubMed ID: 28465139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis.
    Yoosuf N; Maciejewski M; Ziemek D; Jelinsky SA; Folkersen L; Müller M; Sahlström P; Vivar N; Catrina A; Berg L; Klareskog L; Padyukov L; Brynedal B
    Rheumatology (Oxford); 2022 Apr; 61(4):1680-1689. PubMed ID: 34175943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers identified by serum metabolomic analysis to predict biologic treatment response in rheumatoid arthritis patients.
    Takahashi S; Saegusa J; Onishi A; Morinobu A
    Rheumatology (Oxford); 2019 Dec; 58(12):2153-2161. PubMed ID: 31143951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.
    Castro-Villegas C; Pérez-Sánchez C; Escudero A; Filipescu I; Verdu M; Ruiz-Limón P; Aguirre MA; Jiménez-Gomez Y; Font P; Rodriguez-Ariza A; Peinado JR; Collantes-Estévez E; González-Conejero R; Martinez C; Barbarroja N; López-Pedrera C
    Arthritis Res Ther; 2015 Mar; 17(1):49. PubMed ID: 25860297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis.
    Reams J; Berger A; Denio A
    Medicine (Baltimore); 2020 Aug; 99(35):e21827. PubMed ID: 32871905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care.
    Naniwa T; Iwagaitsu S; Kajiura M
    Mod Rheumatol; 2020 Nov; 30(6):948-958. PubMed ID: 31814481
    [No Abstract]   [Full Text] [Related]  

  • 14. Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts.
    Sánchez-Maldonado JM; Cáliz R; López-Nevot MÁ; Cabrera-Serrano AJ; Moñiz-Díez A; Canhão H; Ter Horst R; Quartuccio L; Sorensen SB; Glintborg B; Hetland ML; Filipescu I; Pérez-Pampin E; Conesa-Zamora P; Swierkot J; den Broeder AA; De Vita S; Petersen ERB; Li Y; Ferrer MA; Escudero A; Netea MG; Coenen MJH; Andersen V; Fonseca JE; Jurado M; Bogunia-Kubik K; Collantes E; Sainz J
    Front Immunol; 2021; 12():672255. PubMed ID: 34777329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.
    Eng GP
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs.
    Muñoz-Barrera L; Perez-Sanchez C; Ortega-Castro R; Corrales S; Luque-Tevar M; Cerdó T; Sanchez-Pareja I; Font P; Lopez-Mejías R; Calvo J; Abalos-Aguilera MC; Ruiz-Vilchez D; Segui P; Merlo C; Perez-Venegas J; Ruiz Montesino MD; Rodriguez-Escalera C; Barco CR; Fernandez-Nebro A; Vazque NM; Marenco JL; Montañes JU; Godoy-Navarrete J; Cabezas-Lucena AM; Estevez EC; Aguirre MA; González-Gay MA; Barbarroja N; Escudero-Contreras A; Lopez-Pedrera C
    Biomed Pharmacother; 2024 Apr; 173():116357. PubMed ID: 38479179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion.
    Pérez-Sánchez C; Cecchi I; Barbarroja N; Patiño-Trives AM; Luque-Tévar M; Pérez-Sánchez L; Ibáñez-Costa A; Arias de la Rosa I; Ortega R; Escudero A; Castro MC; Radin M; Roccatello D; Sciascia S; Aguirre MÁ; Collantes E; López-Pedrera C;
    J Cell Mol Med; 2019 Sep; 23(9):6308-6318. PubMed ID: 31347786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants in the TNF pathway impact TNFi response in a mixed population with rheumatoid arthritis.
    Augusto Silva Dos Santos Rodrigues P; Lima de Oliveira A; Mattos Brandão K; de Sá Garcia Landeiro L; Cardoso Calmon L; Victor Andrade Cruz J; Dos Anjos Silva M; Flávia Silva Rocha A; Silva Carvalho de Souza D; Tupiná Alcântara de Moreira A; de Oliveira Santos J; Miranda Barbosa Dos Santos T; Pimentel Pinheiro G; Augusto Souza da Cruz Filho Á; Alexandrina Viana de Figueiredo C; de Moura Santos P; Dos Santos Costa R
    Gene; 2024 Nov; 928():148804. PubMed ID: 39089529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.